SCHEMBL2980438

SCHEMBL2980438

CC1(C)C(=O)NC(=O)N1CCN

nearest known ligand 0.30

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.30
AR P10275 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11550745 0.88
SCHEMBL11250686 0.82 POLB (0.32) POLB
SCHEMBL19049542 0.80 SMN1; SMN2 (0.33) POLB
SCHEMBL11255550 0.80 POLB (0.31) POLB
SCHEMBL5181718 0.78 POLB (0.30) POLBAR
SCHEMBL2981814 0.78 LMNA (0.33)
SCHEMBL376221 0.77 MMP1 (0.33) POLB
SCHEMBL133836 0.77 POLB (0.39) POLBAR
SCHEMBL8638714 0.75 DAO (0.38)
SCHEMBL11642326 0.75 POLB (0.38) POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113943377-B Cellulose antibacterial material with lysine grafted N-halamine type Schiff base structure and preparation method thereof 长春工业大学 2023-03-21 CN claimed
CN-113943377-A Cellulose antibacterial material with lysine grafted N-halamine type Schiff base structure and preparation method thereof 长春工业大学 2022-01-18 CN claimed
CN-113943377-B Cellulose antibacterial material with lysine grafted N-halamine type Schiff base structure and preparation method thereof 长春工业大学 2023-03-21 CN disclosed
CN-113943377-A Cellulose antibacterial material with lysine grafted N-halamine type Schiff base structure and preparation method thereof 长春工业大学 2022-01-18 CN disclosed
EP-1831207-B1 AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS AMGEN INC (US) 2012-11-14 EP disclosed
US-7858785-B2 Aminopyrimidine compounds and methods of use AMGEN INC. (US) 2010-12-28 US disclosed
US-7786132-B2 Aminopyrimidine compounds and methods of use AMGEN INC. (US) 2010-08-31 US disclosed
US-20100010014-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2010-01-14 US disclosed
EP-1831207-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2007-09-12 EP disclosed
US-20070185133-A1 Aminopyrimidine compounds and methods of use AMGEN, INC. (US) 2007-08-09 US disclosed
WO-2006066172-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE AMGEN, INC. (US) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010014-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE PLK1, TYMP, TK2 POLB 16/4885AR 4251/4885
US-20070185133-A1 Aminopyrimidine compounds and methods of use PLK1, TYMP, TK2 POLB 16/4885AR 4251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.